Candidemia Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Albany, United States) "Candidemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Candidemia Market.

As per DelveInsight's assessment, globally, Candidemia pipeline constitutes 4+ key companies continuously working towards developing 4+ Candidemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Request for Sample Report here @ https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Candidemia Pipeline Report:
• Candidemia Companies across the globe are diligently working toward developing novel Candidemia treatment therapies with a considerable amount of success over the years.
• Candidemia companies working in the treatment market are Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals and others, are developing therapies for the Candidemia treatment
• Emerging Candidemia therapies such as Rezafungin, and others are expected to have a significant impact on the Candidemia market in the coming years.
• In January 2024, Cidara Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (U.K.) approved REZZAYO (rezafungin acetate) for the management of invasive candidiasis in adults. REZZAYO is a new once-weekly echinocandin licensed in the United States to treat candidemia and invasive candidiasis in adults.
• In November 2023, Basilea Pharmaceutica Ltd stated that it had signed an asset purchase agreement with Amplyx Pharmaceuticals, Inc., a Pfizer Inc. company, to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. Additionally, Basilea has purchased the rights to a preclinical antifungal chemical.
• In July 2023, T2 Biosystems, Inc. declared that the US Food and Drug Administration (FDA) granted Breakthrough Device status for the Company's Candida auris (C. auris) direct-from-blood molecular diagnostic test.

Candidemia Overview
Candidemia is a serious bloodstream infection caused by Candida species, a type of yeast that normally resides on the skin and mucosal surfaces but can become invasive under certain conditions. It is the most common fungal bloodstream infection and is associated with high morbidity and mortality, particularly in immunocompromised individuals, hospitalized patients, and those with central venous catheters, prolonged antibiotic use, or underlying conditions like diabetes and cancer.

Symptoms of candidemia are often non-specific and may include fever, chills, hypotension, and signs of sepsis that do not improve with antibiotic treatment. If left untreated, the infection can spread to major organs, leading to complications such as endocarditis, meningitis, and kidney or liver dysfunction. Diagnosis is typically confirmed through blood cultures, but newer rapid diagnostic techniques, such as PCR and beta-D-glucan tests, can improve detection speed.

Treatment involves prompt administration of antifungal agents, with echinocandins (e.g., caspofungin, micafungin) as the first-line therapy. In some cases, fluconazole may be used as an alternative. Source control, such as removing infected catheters, is also crucial for successful treatment. Early diagnosis and appropriate antifungal therapy are essential to reducing mortality and improving patient outcomes.

Get a Free Sample PDF Report to know more about Candidemia Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Candidemia Route of Administration
Candidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Candidemia Molecule Type
Candidemia Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Candidemia Pipeline Therapeutics Assessment
• Candidemia Assessment by Product Type
• Candidemia By Stage and Product Type
• Candidemia Assessment by Route of Administration
• Candidemia By Stage and Route of Administration
• Candidemia Assessment by Molecule Type
• Candidemia by Stage and Molecule Type

DelveInsight's Candidemia Report covers around 4+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Candidemia product details are provided in the report. Download the Candidemia pipeline report to learn more about the emerging Candidemia therapies- https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Candidemia Pipeline Analysis:
The Candidemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Candidemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Candidemia Treatment.
• Candidemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Candidemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Candidemia market.

Download Sample PDF Report to know more about Candidemia drugs and therapies- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Candidemia Pipeline Drug Insight
• Coverage: Global
• Key Candidemia Companies: Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals and others.
• Key Candidemia Therapies: Rezafungin, and others.
• Candidemia Therapeutic Assessment: Candidemia current marketed and Candidemia emerging therapies
• Candidemia Market Dynamics: Candidemia market drivers and Candidemia market barriers

Request for Sample PDF Report for Candidemia Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Candidemia Report Introduction
2. Candidemia Executive Summary
3. Candidemia Overview:
4. Candidemia- Analytical Perspective In-depth Commercial Assessment
5. Candidemia Pipeline Therapeutics
6. Candidemia Late Stage Products (Phase II/III)
7. Candidemia Mid Stage Products (Phase II)
8. Candidemia Early Stage Products (Phase I)
9. Candidemia Preclinical Stage Products
10. Candidemia Therapeutics Assessment
11. Candidemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Candidemia Companies
14. Candidemia Key Products
15. Candidemia Unmet Needs
16 . Candidemia Market Drivers and Barriers
17. Candidemia Future Perspectives and Conclusion
18. Candidemia Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Ada-scid Competitive Landscape: https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/licensing-services
Case study: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.